Clinical trials: System Sclerosis
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders
Evaluation of the Impact of Multiple Sclerosis and Its Treatments on Women Fertility
CONTEXT A desire for pregnancy is common in young patients with multiple sclerosis (MS). The impact of MS on women fertility is debated, and the impact of disease-modifying therapies (DMTs) on fertility is not well known.
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Fertility
- Trial name
- FERTIMUS (NCT07164924)
- Testing
- blood sample to analyse AMH level on the serum
- Where
- 27 sites in France, Martinique
- Volunteers
- 800 people
- Sponsor
- University Hospital, Clermont-Ferrand
Multiple Sclerosis
Observational Study in Multiple Sclerosis Patients Treated With Autologous Hematopoietic Stem Cell Transplantation
Observational prospective , multi-center study Primary objective : To gain further homogenous evidence for clinical efficacy of aHSCT in patients undergoing aHSCT for MS as primary indication.
- Trial name
- OMST (NCT04674280)
- Testing
- aHSCT
- Volunteers
- 50 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Systemic Sclerosis
Small Intestinal Mucosal Abnormalities in Systemic Sclerosis Using Capsule Endoscopy
The aim of this prospective study is to determine prevalence and characteristics of small intestinal mucosal abnormalities in 40 patients with systemic sclerosis, using capsule endoscopy.
- Trial name
- sclero-video (NCT00958672)
- Testing
- Endoscopic capsule
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Rouen
Relapsing Remitting Multiple Sclerosis
Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment
In this study the investigators wish to test the hypothesis that the repertoire of solutes secreted by leukocytes isolated from patients with relapsing-remitting forms of Multiple Sclerosis (MS) following 6 months of treatment…
- Trial name
- NCT05171972
- Testing
- Ofatumumab
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Multiple Sclerosis
Improving Workforce Participation and Well-Being in Individuals With Multiple Sclerosis - A Feasability Study
Multiple sclerosis (MS) is a chronic neurodegenerative disease and a leading cause of reduced workforce participation due to neurological illness in Western countries.
- Trial name
- NCT07380295
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Region Gävleborg
Multiple Sclerosis
Immersive Virtual Reality for Upper Limb Rehabilitation in Multiple Sclerosis
Virtual reality (VR) has reported benefits of engagement, immersion, and motivation in rehabilitation and has been proposed to be a solution for long-term engaging rehabilitation methods.
- Trial name
- NCT05320237
- Testing
- Immersive Virtual Reality Intervention
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Glasgow Caledonian University
Amyotrophic Lateral Sclerosis
Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis
The primary objective of the trial is to investigate the survival time (the time from randomization until death or end of the trial) compared between control group and experimental group.
- Trial name
- NCT01879241
- Testing
- Rasagiline
- Where
- 15 sites in Germany
- Volunteers
- 252 people
- Sponsor
- University of Ulm
Systemic Sclerosis, Diffuse Scleroderma
IVIG Treatment in Systemic Sclerosis
The purpose of this research is to study the effects of Privigen (intravenous immunoglobulin) on the skin in patients with scleroderma.
- Trial name
- NCT01785056
- Testing
- Privigen
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Georgetown University
Relapsing-remitting Multiple Sclerosis
Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b
The "SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study" is the follow up study of the "SWiss Atorvastatin and Interferon Beta-1b Trial In Multiple Sclerosis (SWABIMS)" (see…
- Trial name
- NCT01111656
- Testing
- Interferon beta-1b group, Interferon beta-1b/Atorvastatin group
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Multiple Sclerosis, Internuclear Ophthalmoplegia
Internuclear Ophthalmoplegia and Multiple Sclerosis: a Multicenter Retrospective Study
Internuclear ophthalmoplegia is a symptom frequently associated with multiple sclerosis (MS), although other etiologies are possible.
- Trial name
- INO&MS (NCT07560995)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Multiple Sclerosis, Chronic Progressive
Evidence Based Patient Information and Smartphone Accelerometry to Enhance Physical Activity in MS
Due to their ubiquitary distribution, smartphones might serve as an easy way/ possibility to use feedback mechanism in an app-based intervention program to increase physical activity in Multiple Sclerosis (MS) patients.
- Trial name
- PIA (NCT03114293)
- Testing
- Smartphone App
- Volunteers
- 40 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis
Central Pain Study for ABX-1431
This study will determine the safety and tolerability of ABX-1431 in patients with central pain when added on to background pain therapy.
- Conditions
- Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis, Multiple Sclerosis, Longitudinally Extensive Transverse Myelitis
- Trial name
- NCT03138421
- Testing
- ABX-1431 HCl
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people
- Sponsor
- Abide Therapeutics
Amyotrophic Lateral Sclerosis (ALS)
Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine if oral treatment with ONO-2506PO in patients diagnosed with ALS, who have had onset of muscle weakness within 14 months of randomization, could lead to the slowing of decline in…
- Trial name
- NCT00403104
- Testing
- ONO-2506PO
- Where
- 26 sites in Austria, Belgium and 6 more
- Volunteers
- 420 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Relapsing-Remitting Multiple Sclerosis
Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
The primary objective of this study is to evaluate the effect of symptomatic therapies on gastrointestinal-related events reported by participants with relapsing-remitting multiple sclerosis initiating therapy with BG00012…
- Trial name
- TOLERATE (NCT02125604)
- Testing
- dimethyl fumarate
- Where
- 19 sites in Germany
- Volunteers
- 214 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
Cervical Electrical Stimulation for ALS
Veterans are at higher risk than non-Veterans of falling ill with amyotrophic lateral sclerosis (ALS). ALS causes degeneration of motor neurons in both the brain and the spinal cord.
- Trial name
- NCT03411863
- Testing
- CES at rest, CES plus active hand or wrist movements
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera
The primary objective of the study is to describe absolute lymphocyte count (ALC) reconstitution after Dimethyl fumarate (DMF) discontinuation, in Relapsing-Remitting Multiple Sclerosis (RRMS) participants with lymphopenia.
- Trial name
- Lympho-TEC (NCT04756687)
- Testing
- Dimethyl fumarate
- Where
- 32 sites in France
- Volunteers
- 1,507 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motoneurons, with a prevalence around 5/100.000. Respiratory muscle involvement is a major feature in ALS and remains the main prognostic factor.
- Trial name
- NCT00879593
- Testing
- PtcCO2
- Where
- 2 sites in France
- Volunteers
- 66 people
- Sponsor
- Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Multiple Sclerosis
Exercise Intensity and Immune Function in Multiple Sclerosis
This study aims to determine the effect of exercise intensity within a 15 week programme in moderately disabled people with multiple sclerosis (MS).
- Trial name
- NCT02264704
- Testing
- High intensity exericse, Moderate intensity exericse
- Where
- United Kingdom
- Volunteers
- 63 people
- Sponsor
- University of the West of Scotland
Amyotrophic Lateral Sclerosis (ALS)
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
This is a Phase 3, international, multicenter, open-label, long-term extension study. The primary objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral…
- Trial name
- NCT04577404
- Testing
- MT-1186
- Where
- 44 sites in United States, Canada and 4 more
- Volunteers
- 124 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Study of Electrical Impedance Myography (EIM) in ALS
This trial is studying Electrical Impedance Myography (EIM) for measuring muscle health. The trial is studying people with Amyotrophic Lateral Sclerosis (ALS), other neuromuscular diseases, and healthy volunteers to see if the…
- Conditions
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Charcot-Marie-Tooth Disease, Multiple Sclerosis
- Trial name
- NCT02011204
- Testing
- Electrical impedance myography (EIM)
- Where
- 6 sites in United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Skulpt, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.